BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22173053)

  • 1. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
    Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
    Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
    Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
    Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
    Zhang M; Herion TW; Timke C; Han N; Hauser K; Weber KJ; Peschke P; Wirkner U; Lahn M; Huber PE
    Neoplasia; 2011 Jun; 13(6):537-49. PubMed ID: 21677877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
    Connolly EC; Saunier EF; Quigley D; Luu MT; De Sapio A; Hann B; Yingling JM; Akhurst RJ
    Cancer Res; 2011 Mar; 71(6):2339-49. PubMed ID: 21282335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway.
    Sun DY; Wu JQ; He ZH; He MF; Sun HB
    Life Sci; 2019 Oct; 235():116791. PubMed ID: 31465732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
    Jin Y; Cui Z; Li X; Jin X; Peng J
    Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
    Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
    Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
    Ganapathy V; Ge R; Grazioli A; Xie W; Banach-Petrosky W; Kang Y; Lonning S; McPherson J; Yingling JM; Biswas S; Mundy GR; Reiss M
    Mol Cancer; 2010 May; 9():122. PubMed ID: 20504320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.
    Flechsig P; Dadrich M; Bickelhaupt S; Jenne J; Hauser K; Timke C; Peschke P; Hahn EW; Gröne HJ; Yingling J; Lahn M; Wirkner U; Huber PE
    Clin Cancer Res; 2012 Jul; 18(13):3616-27. PubMed ID: 22547771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
    Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
    Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells.
    Xu Y; Tabe Y; Jin L; Watt J; McQueen T; Ohsaka A; Andreeff M; Konopleva M
    Br J Haematol; 2008 Jun; 142(2):192-201. PubMed ID: 18492113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
    Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
    J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimetastatic role of Smad4 signaling in colorectal cancer.
    Zhang B; Halder SK; Kashikar ND; Cho YJ; Datta A; Gorden DL; Datta PK
    Gastroenterology; 2010 Mar; 138(3):969-80.e1-3. PubMed ID: 19909744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
    Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
    Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β1 as possible link between loss of bone mineral density and chronic inflammation.
    Ehnert S; Baur J; Schmitt A; Neumaier M; Lucke M; Dooley S; Vester H; Wildemann B; Stöckle U; Nussler AK
    PLoS One; 2010 Nov; 5(11):e14073. PubMed ID: 21124921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY2109761, Transforming Growth Factor β Receptor Type I and Type II Dual Inhibitor, is a Novel Approach to Suppress Endothelial Mesenchymal Transformation in Human Corneal Endothelial Cells.
    Zhang ZH; Miao YY; Ke BL; Liu K; Xu X
    Cell Physiol Biochem; 2018; 50(3):963-972. PubMed ID: 30355908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.